Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 7/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27089918 | 1.00 | L3MBTL1 (0.65) | L3MBTL1TDP1IDO1AGXTGBA1 | |
| SCHEMBL16727734 | 1.00 | L3MBTL1 (0.65) | L3MBTL1TDP1IDO1AGXTGBA1 | |
| SCHEMBL4728877 | 0.98 | L3MBTL1 (0.62) | L3MBTL1TDP1IDO1AGXTGBA1 | |
| SCHEMBL6512199 | 0.93 | L3MBTL1 (0.59) | L3MBTL1TDP1IDO1AGXTGBA1 | |
| SCHEMBL1427941 | 0.85 | TDP1 (0.54) | L3MBTL1TDP1IDO1AGXTCA1 | |
| SCHEMBL9764497 | 0.85 | TDP1 (0.55) | L3MBTL1TDP1IDO1CALM1NPC1 | |
| SCHEMBL9574168 | 0.85 | TDP1 (0.59) | L3MBTL1TDP1IDO1CALM1CHRM2 | |
| SCHEMBL9574271 | 0.85 | TDP1 (0.55) | L3MBTL1TDP1IDO1CALM1NPC1 | |
| SCHEMBL9574323 | 0.85 | TDP1 (0.63) | L3MBTL1TDP1CALM1MEN1KMT2A | |
| SCHEMBL1354242 | 0.85 | L3MBTL1 (0.56) | L3MBTL1TDP1IDO1AGXTGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287036-A1 | NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND | RIKEN (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2359852-A1 | NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBSTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND | Japan Health Sciences Foundation (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-6531469-B1 | Treatment of myocardial ischemia, chronic stable angina, unstable angina and prinzmetal's angina attacks, silent cardiac ischemia, reinfarction, reocclusion and restenosis | PIERRE FABRE MEDICAMENT (FR) | 2003-03-11 | — | — | US | disclosed |
| EP-1144408-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043391-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287036-A1 | NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND | PLAUR, BST2, SDCBP | L3MBTL1 3725/4885TDP1 3902/4885IDO1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.